Published in J Alzheimers Dis on January 01, 2012
Growth arrest specific 1 (GAS1) is abundantly expressed in the adult mouse central nervous system. J Histochem Cytochem (2013) 0.76
Alzheimer's disease: genes, proteins, and therapy. Physiol Rev (2001) 19.19
Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol (1998) 14.83
Brefeldin A: insights into the control of membrane traffic and organelle structure. J Cell Biol (1992) 13.15
Alzheimer's disease. N Engl J Med (2010) 13.13
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev (2000) 5.40
Amyloid precursor protein trafficking, processing, and function. J Biol Chem (2008) 4.79
Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol (2003) 4.71
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Classification and basic pathology of Alzheimer disease. Acta Neuropathol (2009) 3.24
Sorting GPI-anchored proteins. Nat Rev Mol Cell Biol (2004) 2.77
Detergent-resistant membranes should not be identified with membrane rafts. Trends Biochem Sci (2005) 2.62
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Lipids as targeting signals: lipid rafts and intracellular trafficking. Traffic (2004) 2.28
Evidence for segregation of sphingomyelin and cholesterol during formation of COPI-coated vesicles. J Cell Biol (2000) 2.13
Spatial segregation of gamma-secretase and substrates in distinct membrane domains. J Biol Chem (2005) 1.98
Processing of the beta-amyloid precursor protein and its regulation in Alzheimer's disease. J Neurochem (1995) 1.83
Regulated intramembrane proteolysis--lessons from amyloid precursor protein processing. J Neurochem (2011) 1.79
Amyloid-beta precursor protein processing in neurodegeneration. Curr Opin Neurobiol (2004) 1.59
Genetic heterogeneity of Alzheimer's disease: complexity and advances. Psychoneuroendocrinology (2007) 1.54
Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med (2002) 1.46
TissueInfo: high-throughput identification of tissue expression profiles and specificity. Nucleic Acids Res (2001) 1.38
Membrane rafts in Alzheimer's disease beta-amyloid production. Biochim Biophys Acta (2010) 1.37
Genetic and molecular aspects of Alzheimer's disease shed light on new mechanisms of transcriptional regulation. Genes Brain Behav (2005) 1.36
Selective export of human GPI-anchored proteins from the endoplasmic reticulum. J Cell Sci (2010) 1.25
Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J Alzheimers Dis (2010) 1.24
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Genetics of Alzheimer disease in the pre- and post-GWAS era. Alzheimers Res Ther (2010) 1.18
Lipid Rafts: Linking Alzheimer's Amyloid-β Production, Aggregation, and Toxicity at Neuronal Membranes. Int J Alzheimers Dis (2010) 1.17
Gas1 is related to the glial cell-derived neurotrophic factor family receptors alpha and regulates Ret signaling. J Biol Chem (2006) 1.11
No association between CALHM1 variation and risk of Alzheimer disease. Hum Mutat (2009) 1.11
Glial cell line-derived neurotrophic factor-dependent recruitment of Ret into lipid rafts enhances signaling by partitioning Ret from proteasome-dependent degradation. J Neurosci (2006) 1.11
The role of Gas1 in embryonic development and its implications for human disease. Cell Cycle (2007) 1.08
Trafficking of Alzheimer's disease-related membrane proteins and its participation in disease pathogenesis. J Biochem (2006) 1.04
CALHM1 P86L polymorphism is associated with late-onset Alzheimer's disease in a recessive model. J Alzheimers Dis (2010) 1.03
Trafficking, a key player in regulated intramembrane proteolysis. Semin Cell Dev Biol (2008) 1.01
Modulation of amyloid precursor protein cleavage by cellular sphingolipids. J Biol Chem (2004) 1.00
Hedgehog signaling: cooking with Gas1. Sci STKE (2007) 1.00
Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. BMC Res Notes (2008) 0.99
Is GAS1 a co-receptor for the GDNF family of ligands? Trends Pharmacol Sci (2006) 0.98
Glycosylphosphatidylinositol-anchor intermediates associate with triton-insoluble membranes in subcellular compartments that include the endoplasmic reticulum. Biochem J (1999) 0.96
Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet (2011) 0.94
CALHM1 P86L polymorphism modulates CSF Aβ levels in cognitively healthy individuals at risk for Alzheimer's disease. Mol Med (2011) 0.90
Gas1 is induced during and participates in excitotoxic neuronal death. Mol Cell Neurosci (2002) 0.90
Beyond tissueInfo: functional prediction using tissue expression profile similarity searches. Nucleic Acids Res (2008) 0.85
Growth arrest specific gene 1: a fuel for driving growth in the cerebellum. Cerebellum (2002) 0.83
ER export: more than one way out. Curr Biol (2001) 0.80
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol (2007) 5.98
Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science (2005) 5.49
Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms. J Neurochem (2003) 3.79
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci (2005) 2.94
TMP21 is a presenilin complex component that modulates gamma-secretase but not epsilon-secretase activity. Nature (2006) 2.56
A polymorphism in CALHM1 influences Ca2+ homeostasis, Abeta levels, and Alzheimer's disease risk. Cell (2008) 2.55
Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem (2005) 2.31
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Colocalization of tau and alpha-synuclein epitopes in Lewy bodies. J Neuropathol Exp Neurol (2003) 2.20
Neuropathologic features of frontotemporal lobar degeneration with ubiquitin-positive inclusions with progranulin gene (PGRN) mutations. J Neuropathol Exp Neurol (2007) 2.19
Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron (2003) 2.17
Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model. Am J Pathol (2004) 2.15
A polymorphic gene nested within an intron of the tau gene: implications for Alzheimer's disease. Proc Natl Acad Sci U S A (2002) 2.14
CALHM1 ion channel mediates purinergic neurotransmission of sweet, bitter and umami tastes. Nature (2013) 2.08
Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry (2004) 2.07
Performance-based measures of everyday function in mild cognitive impairment. Am J Psychiatry (2010) 1.96
Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. Arch Gen Psychiatry (2011) 1.94
Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax (2010) 1.91
Passive immunization with anti-Tau antibodies in two transgenic models: reduction of Tau pathology and delay of disease progression. J Biol Chem (2011) 1.91
Age-dependent impairment of cognitive and synaptic function in the htau mouse model of tau pathology. J Neurosci (2009) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Concepts for risk-based surveillance in the field of veterinary medicine and veterinary public health: review of current approaches. BMC Health Serv Res (2006) 1.81
The beleaguered consultation. Br J Gen Pract (2006) 1.77
Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease. Arch Neurol (2005) 1.75
Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem (2006) 1.68
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
Should the practice of medicine be a deontological or utilitarian enterprise? J Med Ethics (2011) 1.62
Traditional markers of excessive alcohol use. Addiction (2003) 1.62
Patients and the new contracts. BMJ (2003) 1.59
Gold for the NHS. What exactly is being bought with this gold? BMJ (2002) 1.55
Control and elimination of porcine reproductive and respiratory syndrome virus. Virus Res (2010) 1.52
Tuberculosis in the UK--time to regain control. BMJ (2011) 1.43
Semantic distance abnormalities in mild cognitive impairment: their nature and relationship to function. Am J Psychiatry (2012) 1.43
Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch Neurol (2002) 1.41
Religious slaughter. Vet Rec (2003) 1.39
The non-principal phenomenon: a threat to continuity of care and patient enablement? Br J Gen Pract (2004) 1.38
Tau passive immunotherapy in mutant P301L mice: antibody affinity versus specificity. PLoS One (2013) 1.29
Calcium signaling in neurodegeneration. Mol Neurodegener (2009) 1.27
Tau phosphorylated at tyrosine 394 is found in Alzheimer's disease tangles and can be a product of the Abl-related kinase, Arg. J Alzheimers Dis (2010) 1.26
An immunohistochemical study of cases of sporadic and inherited frontotemporal lobar degeneration using 3R- and 4R-specific tau monoclonal antibodies. Acta Neuropathol (2006) 1.24
Deregulation of cdk5, hyperphosphorylation, and cytoskeletal pathology in the Niemann-Pick type C murine model. J Neurosci (2002) 1.24
Novel synthetic small-molecule activators of AMPK as enhancers of autophagy and amyloid-β peptide degradation. FASEB J (2010) 1.24
Chronic neuropathological and neurobehavioral changes in a repetitive mild traumatic brain injury model. Ann Neurol (2014) 1.23
AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol (2010) 1.22
Discovering discovery patterns with Predication-based Semantic Indexing. J Biomed Inform (2012) 1.22
Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci (2008) 1.19
The CALHM1 P86L polymorphism is a genetic modifier of age at onset in Alzheimer's disease: a meta-analysis study. J Alzheimers Dis (2010) 1.19
Calcium homeostasis modulator 1 (CALHM1) is the pore-forming subunit of an ion channel that mediates extracellular Ca2+ regulation of neuronal excitability. Proc Natl Acad Sci U S A (2012) 1.16
The core of tau-paired helical filaments studied by scanning transmission electron microscopy and limited proteolysis. Biochemistry (2006) 1.16
Anesthesia-induced hyperphosphorylation detaches 3-repeat tau from microtubules without affecting their stability in vivo. J Neurosci (2008) 1.15
c-Abl in neurodegenerative disease. J Mol Neurosci (2011) 1.15
Conditional neuronal simian virus 40 T antigen expression induces Alzheimer-like tau and amyloid pathology in mice. J Neurosci (2007) 1.14
Tau paired helical filaments from Alzheimer's disease brain and assembled in vitro are based on beta-structure in the core domain. Biochemistry (2004) 1.12
Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade. J Neurochem (2011) 1.10
GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals. Neurobiol Dis (2008) 1.10
Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol (2005) 1.06
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis. Mol Biol Cell (2009) 1.06
Functional assessment of TSC2 variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 1.05
Neuronal c-Abl overexpression leads to neuronal loss and neuroinflammation in the mouse forebrain. J Alzheimers Dis (2011) 1.04
Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology (2010) 1.04
Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis (2008) 1.04
A relationship between environmental degradation and mental health in rural Western Australia. Health Place (2009) 1.03
Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem (2005) 1.02
Intracellular pH regulates amyloid precursor protein intracellular domain accumulation. Neurobiol Dis (2007) 1.02
Sensitive quantitative assays for tau and phospho-tau in transgenic mouse models. Neurobiol Aging (2012) 1.01
QOF. Br J Gen Pract (2007) 1.00
Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease. J Alzheimers Dis (2010) 0.99
Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp Neurol (2011) 0.99
Amyloid-beta peptide degradation in cell cultures by mycoplasma contaminants. BMC Res Notes (2008) 0.99
Molecular evolution and genetics of the Saitohin gene and tau haplotype in Alzheimer's disease and argyrophilic grain disease. J Neurochem (2004) 0.97
Small-molecule activators of AMP-activated protein kinase (AMPK), RSVA314 and RSVA405, inhibit adipogenesis. Mol Med (2011) 0.97
Identification and biology of α-secretase. J Neurochem (2011) 0.97
AMPK inhibitor compound C suppresses cell proliferation by induction of apoptosis and autophagy in human colorectal cancer cells. J Surg Oncol (2012) 0.97
Brain levels of CDK5 activator p25 are not increased in Alzheimer's or other neurodegenerative diseases with neurofibrillary tangles. J Neurochem (2003) 0.96
Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration. Neurosci Biobehav Rev (2007) 0.95
Aging, gender and APOE isotype modulate metabolism of Alzheimer's Abeta peptides and F-isoprostanes in the absence of detectable amyloid deposits. J Neurochem (2004) 0.95
Growth arrest-specific 1 binds to and controls the maturation and processing of the amyloid-beta precursor protein. Hum Mol Genet (2011) 0.94
Amyloid beta protein precursor is phosphorylated by JNK-1 independent of, yet facilitated by, JNK-interacting protein (JIP)-1. J Biol Chem (2003) 0.94
The map is not the territory. Br J Gen Pract (2002) 0.94
Functional assessment of TSC1 missense variants identified in individuals with tuberous sclerosis complex. Hum Mutat (2012) 0.92
Role of peroxisome proliferator-activated receptor gamma in amyloid precursor protein processing and amyloid beta-mediated cell death. Biochem J (2005) 0.92
Progranulin (GRN) in two siblings of a Latino family and in other patients with schizophrenia. Neurocase (2010) 0.91
The L266V tau mutation is associated with frontotemporal dementia and Pick-like 3R and 4R tauopathy. Acta Neuropathol (2003) 0.91